Advertisement
Journal of Hepatology
EASL
Advanced searchSave search
Letter to the Editor| Volume 68, ISSUE 4, P849-851, April 2018

Download started.

Ok

Reply to: “HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient”

  • Author Footnotes
    † Co-first authors.
    Jing Wang
    Footnotes
    † Co-first authors.
    Affiliations
    Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
    Search for articles by this author
  • Author Footnotes
    † Co-first authors.
    Yiqi Yu
    Footnotes
    † Co-first authors.
    Affiliations
    Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
    Search for articles by this author
  • Author Footnotes
    † Co-first authors.
    Zhefeng Meng
    Footnotes
    † Co-first authors.
    Affiliations
    Minhang Branch of Zhongshan Hospital, Fudan University, Shanghai, China
    Search for articles by this author
  • Author Footnotes
    † Co-first authors.
    Chuan Shen
    Footnotes
    † Co-first authors.
    Affiliations
    Department of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang, China
    Search for articles by this author
  • Miaoqu Zhang
    Affiliations
    Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
    Search for articles by this author
  • Peiyu Qian
    Affiliations
    Minhang Branch of Zhongshan Hospital, Fudan University, Shanghai, China
    Search for articles by this author
  • Caiyan Zhao
    Affiliations
    Department of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang, China
    Search for articles by this author
  • Xuanyi Wang
    Affiliations
    Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, China
    Search for articles by this author
  • Yuxian Huang
    Affiliations
    Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
    Search for articles by this author
  • Jiming Zhang
    Affiliations
    Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China

    Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, China
    Search for articles by this author
  • Chao Qiu
    Correspondence
    Corresponding authors. Address: Department of Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Road, Jingan District, Shanghai 200040, China.
    Affiliations
    Minhang Branch of Zhongshan Hospital, Fudan University, Shanghai, China

    Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, China
    Search for articles by this author
  • Wenhong Zhang
    Correspondence
    Corresponding authors. Address: Department of Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Road, Jingan District, Shanghai 200040, China.
    Affiliations
    Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China

    Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, China
    Search for articles by this author
  • Author Footnotes
    † Co-first authors.
Published:November 04, 2017DOI:https://doi.org/10.1016/j.jhep.2017.10.029
Reply to: “HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient”
Previous ArticleHBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient
Next ArticleStomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?
      We thank Wang et al. for their interest in our study on the use of serum HBV RNA to characterize the transcriptionally active viral reservoir in patients receiving nucleos(t)ide analogue (NA) treatment.
      • Wang J.
      • Yu Y.
      • Li G.
      • Shen C.
      • Meng Z.
      • Zheng J.
      • et al.
      Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.
      J Hepatol. 2018; 68 (PMID:28870671): 16-24
      Apart from pregenome RNA, Wang et al. revealed the existence of HBV RNA splicing variants in sera of patients treated with NAs, paving the way for a better understanding of the nature of serum HBV RNA and its clinical implications in the future.
      • Wang J.
      • Sheng Q.
      • Ding Y.
      • Chen R.
      • Sun X.
      • Chen X.
      • et al.
      HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient.
      J Hepatol. 2018; 68 (PMID:29113914): 847-849

      Linked Article

      • HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient
        Journal of HepatologyVol. 68Issue 4
        • Preview
          With great interest, we read the manuscript “Relationship between serum HBV RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients” by Wang et al. published in Journal of Hepatology.1 The authors revealed that serum hepatitis B virus (HBV) RNA levels reflected intrahepatic transcriptional activity of covalently closed circular DNA (cccDNA) and were associated with liver histopathology in patients receiving entecavir (ETV) therapy. Moreover, quasispecies analysis found that serum HBV RNA resembled intrahepatic viral RNA but not cccDNA, implying that the nascent variants of HBV RNA detected in liver biopsy samples were not present in cccDNA under nucleos(t)ide analogues (NAs) treatment.
        • Full-Text
        • PDF
      • Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients
        Journal of HepatologyVol. 68Issue 1
        • Preview
          Hepatitis B virus (HBV) infection is associated with significant morbidity and mortality. At present, 240 million people are estimated to have chronic hepatitis B (CHB) infection worldwide.1,2 Considering its prevalence, monitoring viral replication activity is a vital part of the clinical management of CHB infection. Thus far, serum HBV-DNA load is the only licensed laboratory indicator that directly indicates the quantity of circulating viral particles, thereby reflecting the activity of viral production in the liver.
        • Full-Text
        • PDF
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      Author names in bold designate shared co-first authorship

        • Wang J.
        • Yu Y.
        • Li G.
        • Shen C.
        • Meng Z.
        • Zheng J.
        • et al.
        Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.
        J Hepatol. 2018; 68 (PMID:28870671): 16-24
        View in Article
        • Wang J.
        • Sheng Q.
        • Ding Y.
        • Chen R.
        • Sun X.
        • Chen X.
        • et al.
        HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient.
        J Hepatol. 2018; 68 (PMID:29113914): 847-849
        View in Article
        • Rosmorduc O.
        • Petit M.A.
        • Pol S.
        • Capel F.
        • Bortolotti F.
        • Berthelot P.
        • et al.
        In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA.
        Hepatology. 1995; 22: 10-19
        View in Article
        • Patel N.
        • White S.J.
        • Thompson R.F.
        • Bingham R.
        • Weiss E.U.
        • Maskell D.P.
        • et al.
        HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly.
        Nat Microbiol. 2017; 2: 17098
        View in Article
        • Fu X.D.
        • Ares Jr., M.
        Context-dependent control of alternative splicing by RNA-binding proteins.
        Nat Rev Genet. 2014; 15: 689-701
        View in Article
        • Soussan P.
        • Pol J.
        • Garreau F.
        • Schneider V.
        • Le Pendeven C.
        • Nalpas B.
        • et al.
        Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease.
        J Infect Dis. 2008; 198: 218-225
        View in Article
        • Bayliss J.
        • Lim L.
        • Thompson A.J.
        • Desmond P.
        • Angus P.
        • Locarnini S.
        • et al.
        Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma.
        J Hepatol. 2013; 59: 1022-1028
        View in Article
        • Chen J.
        • Wu M.
        • Wang F.
        • Zhang W.
        • Wang W.
        • Zhang X.
        • et al.
        Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy.
        Sci Rep. 2015; 5: 16459
        View in Article
        • Duriez M.
        • Mandouri Y.
        • Lekbaby B.
        • Wang H.
        • Schnuriger A.
        • Redelsperger F.
        • et al.
        Alternative splicing of hepatitis B virus: a novel virus/host interaction altering liver immunity.
        J Hepatol. 2017; 67: 687-699
        View in Article
        • Wang J.
        • Shen T.
        • Huang X.
        • Kumar G.R.
        • Chen X.
        • Zeng Z.
        • et al.
        Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.
        J Hepatol. 2016; 65: 700-710
        View in Article
        • Rokuhara A.
        • Matsumoto A.
        • Tanaka E.
        • Umemura T.
        • Yoshizawa K.
        • Kimura T.
        • et al.
        Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy.
        J Gastroenterol. 2006; 41: 785-790
        View in Article
        • Jansen L.
        • Kootstra N.A.
        • van Dort K.A.
        • Takkenberg R.B.
        • Reesink H.W.
        • Zaaijer H.L.
        Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues.
        J Infect Dis. 2016; 213: 224-232
        View in Article
        • Giersch K.
        • Allweiss L.
        • Volz T.
        • Dandri M.
        • Lutgehetmann M.
        Serum HBV pgRNA as a clinical marker for cccDNA activity.
        J Hepatol. 2017; 66: 460-462
        View in Article
        • van Bommel F.
        • Bartens A.
        • Mysickova A.
        • Hofmann J.
        • Kruger D.H.
        • Berg T.
        • et al.
        Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.
        Hepatology. 2015; 61: 66-76
        View in Article
        • Fung J.
        • Lai C.L.
        • Seto W.K.
        • Yuen M.F.
        Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.
        J Antimicrob Chemother. 2011; 66: 2715-2725
        View in Article

      Article info

      Publication history

      Published online: November 04, 2017

      Identification

      DOI: https://doi.org/10.1016/j.jhep.2017.10.029

      Copyright

      © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX